Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity

Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity

Background: Programmed death-ligand 1 (PD-L1) is the most validated predictive biomarker used for the treatment of head and neck squamous cell carcinoma (HNSCC) with immune checkpoint inhibitors (ICI). Several gene expression-based signatures surrogate of the activation of IFN-gamma pathway and of t...

Full description

Bibliographic Details
Main Authors: Attignon, V. (Author), Auclair-Perossier, J. (Author), Benzerdjeb, N. (Author), Bouaoud, J. (Author), Crozes, C. (Author), Fayette, J. (Author), Gadot, N. (Author), Kamal, M. (Author), Karabajakian, A. (Author), Le Tourneau, C. (Author), Michon, L. (Author), Saintigny, P. (Author), Zrounba, P. (Author)
Format: Article
Language:English
Published: Elsevier Ltd 2021
Subjects:
adult
advanced cancer
aged
antineoplastic agent
Article
B7-H1 Antigen
cancer recurrence
cancer surgery
cetuximab
clinical article
controlled study
female
follow up
gamma interferon
gene expression
Gene expression
gene expression profiling
genetics
Head and Neck Neoplasms
head and neck squamous cell carcinoma
head and neck tumor
human
human tissue
Humans
immunohistochemistry
male
messenger RNA
neck dissection
neoadjuvant chemotherapy
Neoplasm Recurrence, Local
nuclease protection assay
polymerase chain reaction
programmed death 1 ligand 1
Programmed Death Ligand 1
protein expression
protein expression level
protein p16
RNA sequencing
Squamous Cell Carcinoma of Head and Neck
systemic therapy
tertiary lymphoid structure
transcriptome
Transcriptome
tumor recurrence
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items